SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
Showing session: reset
From Breakthroughs to Backbones: The Evolving Landscape of HIV PrEP
- Sort by:
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
11 of
11
|
Introduction of Speakers (Part 1)
Implants Releasing NRTTI MK-8591 Fail to Protect Macaques Against SHIV Containing the M184V Mutation (ABSTRACT
125)
Charles Dobard
Centers for Disease Control and Prevention, Atlanta, GA, USA
MK-8527 Phase III Dose Selection for Monthly Oral HIV-1 Preexposure Prophylaxis (ABSTRACT
126)
Yash Kapoor
Merck Sharp & Dohme, Rahway, NJ, USA
Final Results of the ANRS PREVENIR Study With Daily or On-Demand Oral PrEP With TDF/FTC in Paris (ABSTRACT
127)
Jean-Michel Molina
Assistance Publique – Hôpitaux de Paris, Paris, France
Twice-Yearly Subcutaneous Lenacapavir for PrEP: Updated HIV-1 Incidence and Safety Data in PURPOSE 1 (ABSTRACT
128)
Nkosiphile Ndlovu
Wits Reproductive Health and HIV Institute, Johannesburg, South Africa
Questions and Answers (Part 1)
Lenacapavir for PrEP: HIV-1 Incidence and Safety From PURPOSE 2 at End of Randomized Blinded Phase (ABSTRACT
129)
Valeria D. Cantos Lucio
Emory University, Atlanta, GA, USA
Resistance Analyses of the PURPOSE Studies Through the End of the Randomized Blinded Phase (ABSTRACT
130)
Stephanie Cox
Gilead Sciences, Inc, Foster City, CA, USA
RCT of Dynamic Choice to Provide Oral PrEP to Postpartum South African Women (ABSTRACT
131)
Dvora L. Joseph Davey
University of California Los Angeles, Los Angeles, CA, USA
Effect of Different Pharmacy PrEP Delivery Models on Initiation and Continuation in Kenya: A cRCT (ABSTRACT
132)
Katrina F. Ortblad
Fred Hutchinson Cancer Center, Seattle, WA, USA
Questions and Answers (Part 2)
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
11 of
11
|
